Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Slides:



Advertisements
Similar presentations
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Quality of Life After Treatment of Laryngeal.
Advertisements

Triangles and dotted lines are for mean values. , P <
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Psychosocial Correlates of Symptoms in Functional Dyspepsia
Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey  Moheddine Younsi, PhD  Value in Health Regional.
Volume 61, Issue 5, Pages (November 2014)
The Impact of Pain Management on Quality of Life
Five-year real world outcomes of GeoForm ring implantation in patients with ischemic mitral regurgitation  Tomasz A. Timek, MD, Robert L. Hooker, MD,
Health-Related Quality of Life Outcome After On-Pump Versus Off-Pump Coronary Artery Bypass Graft Surgery: A Prospective Randomized Study  Reza Motallebzadeh,
Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement  J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,
Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity  Nina K. Grewal,
Changes in evaluation indicators from baseline to 12 weeks per visit.
Percentage of patients achieving EULAR response
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Mu Qin et al. JACEP 2017;j.jacep
Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.
(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.
Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
Univariate predictors of (A) ASDAS ID (<1
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.
Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.
Quality of life of patients with Takayasu’s arteritis
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.
Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.
DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.
Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.
SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.
ID Dr. Natālija Nikrus, Dr. Maija Vikmane, Prof. Oskars Kalējs
Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.
Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.
Clinical response in patients with early and established RA at month 24. *p
Patient-reported quality of life after abdominal aortic aneurysm surgery: A prospective comparison of endovascular and open repair  Badr Aljabri, MD,
Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.
Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.
Percentage of patients with RA achieving DAS28(CRP)<2
Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.
Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.
Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.
DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 5.42 and 5.53 for GP2015 and ETN groups, respectively.
Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.
Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI
J. J. Smith, FRCS, A. M. Garratt, PhD, M. Guest, FRCS, R. M
Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.
Satisfaction with control of RA
Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.
Classification tree with the selected characteristics.
LPA groups display vastly different outcomes.
Multivariable model of adjusted
Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.
Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p
Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.
Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.
Presentation transcript:

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes and disease activity scores at week 24. Positive correlations indicate similar directionality of scales; negative correlations indicate opposing directionality. BP, Bodily Pain; CDAI, Clinical Disease Activity Index; DAS28-CRP, 28-joint Disease Activity using C reactive protein; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue scale; GH, General Health perceptions; HAQ-DI, Health Assessment Questionnaire Disability Index; MH, Mental Health; PF, Physical Functioning; PtGA, patient global assessment of disease activity; RE, Role Emotional; RP, Role Physical; SF-36, Short Form 36 Health Survey V.2. SF, Social Functioning; VT, Vitality. Vibeke Strand et al. RMD Open 2017;3:e000416 Copyright © BMJ Publishing Group & EULAR. All rights reserved.